Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.

Autor: Perrin, Steven¹ (AUTHOR), Ladha, Shafeeq² (AUTHOR), Maragakis, Nicholas³ (AUTHOR), Rivner, Michael H.⁴ (AUTHOR), Katz, Jonathan⁵ (AUTHOR), Genge, Angela⁶ (AUTHOR), Olney, Nicholas⁷ (AUTHOR), Lange, Dale⁸ (AUTHOR), Heitzman, Daragh⁹ (AUTHOR), Bodkin, Cynthia¹⁰ (AUTHOR), Jawdat, Omar¹¹ (AUTHOR), Goyal, Namita A.¹² (AUTHOR), Bornstein, Jeffrey D.¹³ (AUTHOR), Mak, Carmen¹ (AUTHOR), Appel, Stanley H.¹⁴ (AUTHOR) sappel@houstonmethodist.org, Paganoni, Sabrina¹⁵ (AUTHOR) spaganoni@mgh.harvard.edu

Publikováno v: PLoS Medicine. 10/31/2024, Vol. 21 Issue 10, p1-18. 18p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Analysis of Cytokine mRNA and DNA: Detection and Quantitation by Competitive Polymerase Chain Reaction

Autor: Gilliland, Gary, Perrin, Steven, Blanchard, Kerry, Bunn, H. Franklin

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 1990 Apr 01. 87(7), 2725-2729.

Externí odkaz: https://www.jstor.org/stable/2354296

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

Autor: Berry, James D, Paganoni, Sabrina, Atassi, Nazem, Macklin, Eric A, Goyal, Namita, Rivner, Michael, Simpson, Ericka, Appel, Stanley, Grasso, Daniela L, Mejia, Nicte I, Mateen, Farrah, Gill, Alan, Vieira, Fernando, Tassinari, Valerie, Perrin, Steven

Publikováno v: Muscle & Nerve
Berry, James D; Paganoni, Sabrina; Atassi, Nazem; Macklin, Eric A; Goyal, Namita; Rivner, Michael; et al.(2017). Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.. Muscle & nerve, 56(6), 1077-1084. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/5513221p

Introduction Immune activation has been implicated in progression of amytrophic lateral sclerosis (ALS). Oral fingolimod reduces circulating lymphocytes. The objective of this phase IIa, randomized, controlled trial was to test the short‐term safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::691ebd15857579dada48b10620919769
http://europepmc.org/articles/PMC5724488

Quality Improvement Initiatives to Assess and Improve PET/CT Injection Infiltration Rates at Multiple Centers.

Autor: Wong, Terence Z., Benefield, Thad, Masters, Shane, Kiser, Jackson W., Crowley, James, Osborne, Dustin, Mawlawi, Osama, Barnwell, James, Gupta, Pawan, Mintz, Akiva, Ryan, Kelley A., Perrin, Steven R., Lattanze, Ronald K., Townsend, David W.

Publikováno v: Journal of Nuclear Medicine Technology; 12/1/2019, Vol. 47 Issue 4, p326-331, 6p, 1 Color Photograph, 4 Charts